Hamza Maged, Doleys Daniel M, Saleh Islam A, Medvedovsky Andrew, Verdolin Michael H, Hamza Monalyce
Anesthesiology/PMR, VCU Spine Center, Virginia Commonwealth University, Richmond, VA, USA.
The Doleys Pain Clinics, Birmingham, AL, USA.
Neuromodulation. 2015 Oct;18(7):636-48; discussion 649. doi: 10.1111/ner.12342. Epub 2015 Aug 26.
The study aims to compare intrathecal (IT) boluses to continuous infusion trialing techniques prior to implantation of drug delivery systems (DDS) for the treatment of severe intractable chronic nonmalignant pain.
This is a prospective, randomized, head-to-head long-term outcome study.
Forty patients with comparable patient demographics were randomly assigned to two cohorts. Cohort A trialed with intermittent boluses; Cohort B trialed with continuous infusion. One patient failed trial in each group. Nineteen patients were implanted in each group. Follow-up was for 36 months with intervals at 6, 12, 18, 24, 36 months. The Brief Pain Inventory was used was used for assessment.
We used the Brief Pain Inventory to measure pain (worst and average), physical function (walking, normal work, and general activity), behavioral function (mood, sleep, and relations with others), IT dose, and oral opioid use.
We observed statistically significant reduction in pain and improvement of function in both cohorts following DDS implantation throughout the observation period. The IT dose remained virtually unchanged throughout as well, with overall limited dose escalation. Oral opioid use was significantly reduced. There was no statistically significant difference in prediction of trial success or long-term outcomes between the two cohorts.
Low-dose IT opioids via DDS can provide significant and long-lasting reduction in pain, and improvement in function (physical and behavioral) for patients with chronic nonmalignant pain. The two trialing techniques tested, intermittent boluses, and continuous infusion delivered intrathecally showed no clinical significance difference in terms of predicting trial success or long-term outcomes.
本研究旨在比较在植入药物输送系统(DDS)治疗重度顽固性慢性非恶性疼痛之前,鞘内(IT)推注与持续输注试验技术。
这是一项前瞻性、随机、直接比较的长期结局研究。
40例具有可比人口统计学特征的患者被随机分为两组。A组采用间歇性推注进行试验;B组采用持续输注进行试验。每组各有1例患者试验失败。每组各有19例患者植入DDS。随访36个月,随访间隔为6、12、18、24、36个月。使用简明疼痛量表进行评估。
我们使用简明疼痛量表来测量疼痛(最严重和平均疼痛程度)、身体功能(行走、正常工作和一般活动)、行为功能(情绪、睡眠和与他人的关系)、IT剂量以及口服阿片类药物的使用情况。
在整个观察期内,两组患者在植入DDS后均观察到疼痛有统计学意义的减轻和功能改善。IT剂量在整个过程中也几乎保持不变,总体剂量增加有限。口服阿片类药物的使用显著减少。两组在试验成功预测或长期结局方面无统计学显著差异。
通过DDS给予低剂量IT阿片类药物可显著且持久地减轻慢性非恶性疼痛患者的疼痛,并改善其功能(身体和行为方面)。所测试的两种试验技术,即鞘内间歇性推注和持续输注,在预测试验成功或长期结局方面无临床显著差异。